- Investing Ideas
- /
- Polish Pharmaceuticals & Biotech Potentially Undervalued Companies
Polish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
8
Companies with a Value score of at least 3, ordered by Value score
8 companies
Selvita
Market Cap: zł554.3m
Operates as a contract research organization worldwide.
SLV
zł30.20
7D
6.3%
1Y
-55.4%
Bayer
Market Cap: zł25.1b
Operates as a life science company worldwide.
BAY
zł108.66
7D
-4.6%
1Y
-4.3%
Novo Nordisk
Market Cap: zł2.0t
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
NVO
zł254.40
7D
-3.8%
1Y
n/a
Sopharma AD
Market Cap: zł1.2b
Produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally.
SPH
zł15.00
7D
-2.0%
1Y
12.8%
Stem Cells Spin
Market Cap: zł9.8m
Operates as a biotechnology company in Poland.
SCS
zł0.24
7D
13.3%
1Y
-44.7%
Genomed Spólka Akcyjna
Market Cap: zł33.8m
Provides DNA sequencing and analysis, and diagnostics of congenital diseases in Poland.
GEN
zł25.60
7D
-1.5%
1Y
-8.6%
Krka d. d
Market Cap: zł5.9b
A generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally.
KRK
zł830.00
7D
2.2%
1Y
36.5%
Celon Pharma
Market Cap: zł1.2b
An integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations.
CLN
zł23.00
7D
5.5%
1Y
45.6%